Deal of the Day — limited-time pharmacy picks!
Borviz T 3.5mg Injection

Borviz T 3.5mg Injection

Prescription requiredRx Required

Salt Composition: Bortezomib Injection IP

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

1 Injection

About The Product

​Multiple Myeloma, Mantle Cell Lymphoma​

Description

Borviz T 3.5mg Injection is an anti-cancer medication. It is used in the treatment of multiple myeloma and mantle cell lymphoma.

Its active ingredient is Bortezomib Injection IP which belongs to the class of proteasome inhibitor. It works by blocking the proteasome, a cellular structure responsible for breaking down damaged or unwanted proteins.

The medicine does not provide a permanent cure but helps control the growth of cancer cells. It should be used consistently as prescribed by a doctor, under medical supervision to achieve the best result.

Indication

Multiple myeloma and mantle cell lymphoma

Common Side Effects

  • Borviz T 3.5mg Injection may cause acute and chronic side effects.
  • Some of the symptoms may resolve on their own but some need proper medical attention to cure.
  • Common ones include: ● High blood pressure ● Breathlessness ● Fungal infection ● Anemia ● Itching ● Pneumonia ● Dry skin ● Gastronintestinal bleeding ● Dehydration ● Motor neuropathy

Dosage And Duration

  • Consult the doctor about proper dosage and duration of Borviz T 3.5mg Injection as it may vary depending on the medical condition.
  • Try to take it with food to help reduce stomach upset and always follow thew doctor instructions carefully.
  • Do not take it in the wrong way, as improper usage may reduce the effectiveness of the medication and cause serious side effects.

Mechanism Of Action

Borviz T 3.5mg Injection is targeted therapy. It works by blocking the proteasome, a protein which is responsible for the growth of cancer cells in the body.

Proteasome inhibitor which is present in the Injection, it blocks the the cancer causing enzyme and stop the growth of tumor in the body. This helps in slowing down the disease progression and allows the body to damaged cancer cells more effectively.

Safety Advice

Alcohol
While taking Borviz T 3.5mg Injection, avoid using alcohol as it may interfere with the treatment and making it less effective in controlling the disease.
Driving
Borviz T 3.5mg Injection show side effects such as dizziness and sleepiness, doctors do not suggest driving at the time when you are taking the dose.
Pregnancy
Pregnant women avoid taking Borviz T 3.5mg Injectionn as it contains a potent anti-cancer agent that may harm the developing fetus.
Kidney
Patient with a kidney cancer avoid taking Borviz T 3.5mg Injection because this medication is specifically designed to treat certain cancers.
Liver
Borviz T 3.5mg Injection is not recommended to liver patients because impaired liver functions can affect how the medication is processed in the body.

Reference

• Duggett, N. A., & Flatters, S.

J. (2017).

Characterization of a rat model of bortezomib‐induced painful neuropathy. British journal of pharmacology, 174(24), 4812-4825. • Yamamoto, S., Kawashiri, T., Higuchi, H., Tsutsumi, K., Ushio, S., Kaname, T., ... & Egashira, N.

(2015). Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats.

Journal of pharmacological sciences, 129(1), 43-50. • Moschetti, G., Amodeo, G., Maftei, D., Lattanzi, R., Procacci, P., Sartori, P., ... & Franchi, S. (2019).

Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. Journal of Neuroinflammation, 16(1), 89. • Xie, J.

D., Chen, S. R., Chen, H., & Pan, H.

L. (2017).

Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology, 123, 477-487. • Tung, D., Cheung, P.

H., Kaur, P., Foreman, O., Kavirayani, A., Hain, H. S., & Saha, S.

(2011). Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.

Pharmacology, 88(1-2), 100-113.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026